-
公开(公告)号：KR1020000024542A
公开(公告)日：2000-05-06
申请号：KR1020000007988
申请日：2000-02-19
Applicant: 대한민국 (식품의약품안전처장)
Abstract: PURPOSE: Extract from STAPF showing excellent effect in the HBV medicine field is provided, which has lower toxicity than any other existing compounds, so the extract from STAPF can be used as a safe and effective medicine for hepatitis B. CONSTITUTION: Extract from STAPF is gained from stems of STAPF. The extracting process comprises of: drying the stems thoroughly at place being well ventilated, or sunning the stems after drying till 60% dried state at place being well ventilated; adding 1L of water per 100g of dried STAPF; heating and gyrating for 2-3hrs at 100°C; extracting only 1 time. Dried powder type of the extract after freeze-drying, and water-soluble part of the extract by centrifuging after dissolving the dried powder are also used as an effective ingredient in the medicine for hepatitis B.
Abstract translation: 目的：提供在HBV药物领域表现出优异疗效的STAPF提取物，其毒性低于其他现有化合物，因此STAPF提取物可用作乙型肝炎安全有效的药物。构成：STAPF提取物为 从STAPF的茎获得。 提取方法包括：在通风良好的地方彻底干燥茎，或干燥后将茎干晒干至60％干燥状态，通风良好; 每100g干STAPF加入1L水; 在100°C加热旋转2-3小时; 仅提取1次。 冷冻干燥后的干粉提取物，溶解干燥粉末后通过离心分离提取物的水溶性部分也用作乙型肝炎药物中的有效成分。
-
公开(公告)号：KR1020130102776A
公开(公告)日：2013-09-23
申请号：KR1020120023878
申请日：2012-03-08
Applicant: 대한민국 (식품의약품안전처장)
CPC classification number: C12Q1/6827 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , G01N33/15 , G01N2800/52
Abstract: PURPOSE: A method for predicting drug response to celecoxib using the genotype of cytochrome p450 2C9 (CYP2C9) gene is provided to analyze the genotype of CYP2C9 gene for predicting drug response to celecoxib and to present a proposal on drug approvals in consideration of Korean pharmacogenomics. CONSTITUTION: A method for analyzing the genotype of CYP2C9 gene for predicting drug response to celecoxib comprises the steps of: acquiring exon 2 and exon 7 of a gene encoding CYP2C9 from genomic DNA and sequencing exon 2 and exon 7; detecting single nucleotide polymorphisms (SNPs) in each determined base sequence, wherein 101^th base (T) of sequence number 1 (exon 2) in CYP2C9 is substituted with C (CYP2C9*13) and 114^th base (A) of sequence number 2 (exon 7) in CYP2C9 is substituted with C (CYP2C9*3); and determining if the genotype of CYP2C9 belongs to the extensive metabolizer (EM) group or intermediate metabolizer (IM) group using the detected SNP. A method for predicting drug response to celecoxib by each CYP2C9 genotype comprises the steps of: orally administering 120-250 mg of celecoxib to each of the EM group and the IM group; and comparing the area under the concentration-time curve (AUC) by each genotype and computing a dosage of celecoxib by each genotype. [Reference numerals] (AA) Elapse time after injecting (hr)
Abstract translation: 目的：提供使用细胞色素p450 2C9（CYP2C9）基因的基因型预测药物对塞来昔布药物反应的方法，以分析CYP2C9基因的基因型，以预测药物对塞来昔布的反应，并提出考虑韩国药物基因组学的药物批准建议。 构成：分析CYP2C9基因基因型预测塞来昔布药物反应的方法，包括以下步骤：从基因组DNA和测序外显子2和外显子7获得编码CYP2C9基因的外显子2和外显子7; 检测每个确定的碱基序列中的单核苷酸多态性（SNP），其中CYP2C9中序列号1（外显子2）的第101位碱基（T）被C（CYP2C9 * 13）和第114位碱基（A）序列替代 CYP2C9中第2（外显子7）被C（CYP2C9 * 3）取代; 并使用检测到的SNP确定CYP2C9的基因型是否属于广泛代谢（EM）组或中间代谢（IM）组。 预测每种CYP2C9基因型对塞来昔布的药物反应的方法包括以下步骤：向EM组和IM组口服120-250mg塞来昔布; 并比较每种基因型浓度 - 时间曲线下面积（AUC），并计算每种基因型的塞来昔布剂量。 （标号）（AA）注射后经过时间（hr）
-
公开(公告)号：KR101301872B1
公开(公告)日：2013-08-30
申请号：KR1020120015167
申请日：2012-02-15
Applicant: 대한민국 (식품의약품안전처장)
Abstract: 본 발명은 시토크롬 P450 2C19(CYP2C19)를 암호화하는 유전자의 일배체형 분석방법, 분석키트 및 이를 이용한 CYP2C19 효소의 활성예측방법에 관한 것이다. 좀 더 구체적으로, 본 발명은 한국인의 CYP2C19 유전자에 위치한 기존에 알려진 단일염기다형성(SNP)에 더하여 신규의 SNP를 추가 발굴하여, 특정 일배체형(Haplotype) 정보를 확보하였는 바, 이 일배체형을 분석할 수 있는 프라이머를 이용한 일배체형 분석방법, 분석키트 및 이를 이용하여 CYP2C19 효소의 활성을 예측하는 방법에 관한 것이다. 본 발명에 의하면, 란소프라졸 대사에 관여하는 CYP2C19의 약물대사효소 활성 지표로서 일배체형을 제공할 수 있으며, 유사약물의 약동 및 약력학적 특성을 파악함으로써 CYP2C19에 의해 대사되는 의약품의 평가 및 가교시험에 대한 지표로서 활용할 수 있다.
-
公开(公告)号：KR1020120031387A
公开(公告)日：2012-04-03
申请号：KR1020100092900
申请日：2010-09-24
Applicant: 대한민국 (식품의약품안전처장)
CPC classification number: C12Q1/6827 , C12Q2600/156 , C12Q2600/172
Abstract: PURPOSE: An analysis kit for haplotypes of a UGT1A1 gene promoter is provided to predict the expression level of the UGT1A1 gene and to develop drugs. CONSTITUTION: A method for analyzing haplotypes of the human UGT1A1 gene comprises: a step of performing PCR using a human UGT1A1 gene promoter or fragment thereof; a step of analyzing the base sequence of a DNA product; and a step of determining the presence of an SNP of -1352 A>C(3676th base of sequence number 8) and -997 G>A(4031th base of sequence number 8).
Abstract translation: 目的：提供UGT1A1基因启动子单体型分析试剂盒，以预测UGT1A1基因的表达水平，开发药物。 构成：分析人UGT1A1基因的单元型的方法，包括：使用人UGT1A1基因启动子或其片段进行PCR的步骤; 分析DNA产物的碱基序列的步骤; 以及确定-1352A> C（序列号8的第3676位）和-997G> A（序列号8的第4031位）的SNP的存在的步骤。
-
公开(公告)号：KR101360109B1
公开(公告)日：2014-02-12
申请号：KR1020110127108
申请日：2011-11-30
Applicant: 대한민국 (식품의약품안전처장) , 경희대학교 산학협력단 , 서울대학교산학협력단
IPC: A61K31/7048 , A61K31/70 , A61P25/28
CPC classification number: A61K31/7048 , A23L2/52 , A23L33/10 , A23L33/135 , A23V2002/00 , A61K36/185 , A61K36/42 , A61K36/47 , A61K36/48 , A61K36/725
Abstract: 본 발명의 스피노신 또는 스피노신 함유 생약 추출물을 포함하는 약학 조성물은 인지기능 장애 질환을 예방 및 치료하는 조성물로, 기억 및 학습 능력을 효과적으로 향상시켜 치매 및 건망증과 같은 인지기능 장애 질환을 효과적으로 치료 및 예방할 수 있다.
Abstract translation: 本发明的药物组合物，其含有刺糖苷或含刺糖多糖的草药提取物，是用于预防和治疗认知功能障碍的组合物，可有效提高记忆力和学习能力，有效治疗和预防认知功能障碍如痴呆 和健忘症。
-
Patent Agency Ranking
公开(公告)号：KR1020130102777A
公开(公告)日：2013-09-23
申请号：KR1020120023879
申请日：2012-03-08
Applicant: 대한민국 (식품의약품안전처장)
CPC classification number: C12Q1/6827 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , G01N33/15 , G01N2800/52
Abstract: PURPOSE: A method for predicting drug response to omeprazole using the genotype of cytochrome p450 2C19 (CYP2C19) gene is provided to analyze the genotype of CYP2C19 gene for predicting drug response to omeprazole and to present a proposal on drug approvals in consideration of Korean pharmacogenomics. CONSTITUTION: A method for analyzing the genotype of CYP2C19 gene for predicting drug response to omeprazole comprises the steps of: acquiring exon 4 and exon 5 of a gene encoding CYP2C19 from genomic DNA and determining each base sequence; detecting single nucleotide polymorphisms (SNPs) of each base sequence, wherein 39th base (G) of sequence number 1 (exon 5) is substituted with A (CYP2C19*2) and 155th base (G) of sequence number 2 (exon 4) is substituted with A (CYP2C19*3); and determining if the genotype of CYP2C19 belongs to extensive metabolizer (EM) group, intermediate metabolizer (IM) group, or poor metabolizer (PM) group using the detected SNP. A method for predicting drug response to omeprazole by each CYP2C19 genotype comprises the steps of: orally administering 20-80 mg of omeprazole to each of the EM, IM, and PM groups; and comparing the area under the concentration-time curve (AUC) by each genotype and computing a dosage of omeprazole by each genotype. [Reference numerals] (AA) Omeprazole (ng/mL); (BB) Elapse time after injecting (hr)
Abstract translation: 目的：提供使用细胞色素p450 2C19（CYP2C19）基因的基因型预测奥美拉唑药物反应的方法，以分析CYP2C19基因的基因型，以预测对奥美拉唑的药物反应，并提出考虑韩国药物基因组学的药物批准建议。 构成：分析CYP2C19基因基因型预测奥美拉唑药物应答的方法，包括以下步骤：从基因组DNA中获得编码CYP2C19基因的外显子4和外显子5，并确定每个碱基序列; 检测每个碱基序列的单核苷酸多态性（SNP），其中序列号1（外显子5）的第39位碱基（G）被序列号2（外显子4）的A（CYP2C19 * 2）和第155位碱基（G）取代为 用A（CYP2C19 * 3）取代; 并使用检测到的SNP确定CYP2C19的基因型是否属于广泛代谢（EM）组，中间代谢者（IM）组或不良代谢者（PM）组。 用于预测每种CYP2C19基因型对奥美拉唑的药物反应的方法包括以下步骤：向每个EM，IM和PM组口服20-80mg奥美拉唑; 并比较各基因型浓度 - 时间曲线下面积（AUC），并计算每种基因型的奥美拉唑剂量。 （AA）奥美拉唑（ng / mL）; （BB）注射后经过时间（小时）
-
公开(公告)号：KR1020130093920A
公开(公告)日：2013-08-23
申请号：KR1020120015167
申请日：2012-02-15
Applicant: 대한민국 (식품의약품안전처장)
CPC classification number: C12Q1/6827 , C12Q2600/106 , C12Q2600/156 , C12Q2600/172
Abstract: PURPOSE: A method of analyzing a CYP2C19 genotype for predicting the effect of lansoprazole is provided to supply a haplotype as a drug-metabolizing enzyme activity index of CYP2C19 engaging in a lansoprazole metabolism and be used as an index about the evaluation of medical supplies metabolized by the CYP2C19 and a cross linkage test by grasping the pharmacokinetics characteristic of equivalent drugs. CONSTITUTION: A method of predicting the lansoprazole metabolic activation of a CYP2C19 protein comprises: a step of determining the each base sequence of the promoter of a gene ciphering cytochrome P450 2C19 (CYP2C19) from genomic DNA, exon 4, exon 5, intron 5 and intron 7; a step of detecting the presence of single nucleotide polymorphism (SNP) in the determined each base sequence; a step of identifying the CYP2C19 gene of experimentee with one among haplotype H1-H3 by using the detected SNP; a step of determining whether the identified haplotype belongs to a haplotype combination group consisting of extensive metabolizer (EM), hetero extensive metabolizer (hetero EM) and poor metabolizer (PM) by assembling the identified haplotype with base pairs; and a step of predicting the lansoprazole metabolic activation of the CYP2C19 protein by using the confirmed haplotype combination group. The lansoprazole metabolic activity is the highest when the haplotype combination group belongs to the EM and is lowest when the haplotype combination group belongs to the PM.
Abstract translation: 目的：提供一种分析CYP2C19基因型以预测兰索拉唑效应的方法，以提供单倍型作为参与兰索拉唑代谢的CYP2C19的药物代谢酶活性指数，并用作关于由 CYP2C19和通过抓取等效药物的药代动力学特征进行交联试验。 组成：预测CYP2C19蛋白的兰索拉新陈代谢活化的方法包括：从基因组DNA，外显子4，外显子5，内含子5中确定加密细胞色素P450 2C19（CYP2C19）基因的启动子的每个碱基序列的步骤，以及 内含子7 检测确定的每个碱基序列中单核苷酸多态性（SNP）的存在的步骤; 通过使用检测到的SNP，在单倍型H1-H3中鉴定实验者的CYP2C19基因的步骤; 通过将识别的单倍型与碱基对组合来确定所识别的单倍型是否属于由广泛代谢（EM），杂广泛代谢（异质EM）和不良代谢者（PM）组成的单倍型组合组的步骤; 以及通过使用确认的单倍型组合组预测CYP2C19蛋白的兰索拉唑代谢活化的步骤。 当单倍型组合属于EM时，兰索拉唑代谢活性最高，单倍型组合属于PM时，代谢活性最低。
-
公开(公告)号：KR101277793B1
公开(公告)日：2013-06-25
申请号：KR1020100092900
申请日：2010-09-24
Applicant: 대한민국 (식품의약품안전처장)
Abstract: 본 발명은 한국인을 대상으로 UGT1A1를 암호화하는 유전자의 프로모터 부위내에 위치한 단일염기다형성(SNP)로부터 특정 일배체형(Haplotype)을 결정하였으며, 이 특정 일배체형(Haplotype)을 분석할 수 있는 상기 유전자 프로모터의 증폭용 프라이머를 포함하는 UGT1A1 유전자 프로모터의 일배체형의 분석키트 및 이를 이용한 분석방법에 관한 것이다. 본 발명에 따른 분석키트 및 분석 방법을 이용하면, UGT1A1 유전자의 발현 정도를 예측할 수 있으며, 또한, 이에 따라 개인간 유전형의 차이에 따른 맞춤의약을 포함하여 UGT1A1에 의하여 대사되는 약물의 개발에 널리 활용할 수 있다.
-
公开(公告)号：KR101261873B1
公开(公告)日：2013-05-14
申请号：KR1020110084092
申请日：2011-08-23
Applicant: 경희대학교 산학협력단 , 대한민국 (식품의약품안전처장)
CPC classification number: Y02A50/481 , Y02A50/483
Abstract: 본발명은식중독을유발하는살모넬라에특이적사멸능을갖는신규박테리오파지(bacteriophage)에관한것으로, 더욱구체적으로는살모넬라균이서식할수 있는곳에서시료를채취하여살모넬라균을특이적으로사멸시킬수 있는박테리오파지를분리하고, 분리된박테리오파지가형태학적분류및 DNA 중합효소의아미노산서열상포도비리데과피에코32-유사바이러스속에속하는신규한박테리오파지임을확인하여기탁하였으며, 상기수탁번호 KCTC18211P로기탁된박테리오파지 Salmonella phage SP(SalP)가살모넬라균들만을선택적으로감염시켜사멸시키는것을확인하였다. 따라서, 본발명의신규박테리오파지 SalP는살모넬라균에의해유발되는질환의예방또는치료용약학적조성물, 세균사멸용조성물, 미생물제제, 항생제, 소독제, 식품첨가제, 및사료첨가제로유용하게사용될수 있다.
-
公开(公告)号：KR101261872B1
公开(公告)日：2013-05-14
申请号：KR1020110084225
申请日：2011-08-23
Applicant: 경희대학교 산학협력단 , 대한민국 (식품의약품안전처장)
Abstract: 본발명은소화관내대사계를대신하여시험관내에서의약품/식품성분등의독성평가또는생리활성평가를위해사용되는분변효소액(Fecalase)을대체할수 있는사람의소화관내에서분리한장내미생물로제조한장내미생물효소복합체(intestinal microbial enzyme mixture, enzyme mix)및이의제조방법에관한것으로, p-나이트로페닐-&bgr;-D-글루커로니드, p-나이트로페닐-&bgr;-D-자일로파이라노시드, 나이트로페닐-α-L-람노파이라노시드및 p-나이트로페닐-&bgr;-D-글루코파이라노시드에대해기질활성을갖는장내미생물효소복합체를에임즈시험에대사활성계로적용하였을때, 기존에소화관내대사계로사용되어왔던피칼라제를적용했을때와유의적으로복귀돌연변이원수가증가함을확인하였으므로, 본발명의장내미생물복합체를소화관내대사계에대한대사활성계로이용하여, 유전독성평가시험인시험관내 염색체이상시험(In vitro Chromosomal Aberration Assay), 시험관내 소핵시험(In vitro Micronucleus Assay), 쥐임파종분석(Mouse Lymphoma Assay, MLA), 시험관내 포유류세포소핵시험(In vitro Mammalian Cell Micronucleus Test), 코멧분석(Comet Assay), 포유류정원세포염색체이상분석(Mammalian Spermatogonial Chromosome Aberration Assay), SOS 크로모테스트(SOS chromotest) 및복귀돌연변이시험인에임즈시험(Bacterial Reverse Mutation Test, Ames Test)법, 또는생리활성평가인전자공여능(Electron donating ability)평가, SOD(Superoxide dismutase) 유사활성평가, 아질산염분해작용측정(Nitrite scavenging ability)을통한항산화활성평가및 항알러지효과평가에적용할수 있다.
-
-
-
-
-
-
-
-
-
Search Results
24
records
(took 0.029 seconds)
